Physician profile
Mark J Mendeszoon
NPI 1356328538
$172,718.18
in general payments reported to CMS, 2019-2025
34 companies · $9,747 in 2025
The $9,747 reported for 2025 was more than what 96% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $19K · 2021: $23K · 2022: $23K · 2023: $52K · 2024: $18K · 2025: $9,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Travel and Lodging: $12K · Food and Beverage: $5,619 · Royalty Or License: $2,853 · Grant: $2,500 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,863.25 |
| Travel and Lodging | $11,545.70 |
| Food and Beverage | $5,618.59 |
| Royalty Or License | $2,853.15 |
| Grant | $2,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $88,291.34 | 2019-2025 | Truelok, Galaxy Fixation System, Truelok System |
| Linvatec Corporation | $18,484.22 | 2023-2025 | Quantum, Neospan, Fracture and Correction Colag 2 |
| In2bones USA, LLC | $14,818.74 | 2019-2022 | |
| Royal Biologics, INC. | $10,559.18 | 2020-2022 | |
| Crossroads Extremity Systems, LLC | $9,558.53 | 2019-2021 | |
| Dne LLC | $8,984.29 | 2023 | Seal |
| Integra Lifesciences Corporation | $5,406.88 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medshape, INC. | $4,989.53 | 2023-2025 | Dynanail, Dynanail Hybrid, Dynanail Helix, Washer, 15 Mm |
| Stryker Corporation | $2,153.46 | 2019-2025 | Infinity Adaptis, Variax, Citrefix |
| Ascension Orthopedics, INC. | $2,039.58 | 2019-2020 | |
| Smith+Nephew, INC. | $2,038.80 | 2019-2023 | Panta 2 |
| Trilliant Surgical LLC. | $1,259.96 | 2024 | Arsenal Sinus Support Plate |
| Medtronic, INC. | $1,117.02 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Novastep INC. | $969.96 | 2022-2023 | Pecaplasty, Peca Bunion Correction System |
| Medline Industries Lp | $733.19 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gramercy Extremity Orthopedics LLC | $475.00 | 2020 | |
| Biotissue Holdings INC. | $162.28 | 2022 | |
| Restor3d, INC. | $143.22 | 2024 | |
| Nevro Corp. | $119.60 | 2023-2024 | Senza |
| Averitas Pharma INC. | $76.91 | 2024 | Qutenza |
| Vericel Corporation | $49.36 | 2019-2023 | Maci |
| Ethicon US, LLC | $44.09 | 2024 | Surgicel Nu-Knit |
| Rock Medical Orthopedics, INC. | $40.16 | 2023 | |
| Moximed, INC | $29.44 | 2025 | Misha Knee System, Small, Left |
| Zyla Life Sciences, INC. | $26.84 | 2019 | |
| Triad Life Sciences INC. | $23.21 | 2022 | |
| Pacira Therapeutics, INC. | $19.37 | 2019 | |
| Bioventus LLC | $16.56 | 2023 | Exogen Ultrasound Bone Healing System |
| Davol INC. | $15.80 | 2021 | |
| Solventum Corporation | $15.65 | 2025 | Prevena, Activ.A.C., Promogran Prisma |
| Organogenesis INC. | $14.72 | 2024 | Puraply Franchise |
| Horizon Therapeutics Plc | $14.11 | 2020 | |
| Globus Medical, INC. | $14.00 | 2021 | |
| Hydrocision, INC. | $13.18 | 2024 | Tenjet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$175,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mendeszoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.